Genetic engineering and personalized cell therapies could transform health care. In recent years, stem cells and gene-editing tools like CRISPR have been making headlines for the possibilities they offer to treat diseases, including cancer. But engineering cells is a slow, labor-intensive process, making it difficult to produce personalized therapies at scale.
The startup Kytopen, co-founded by MIT Associate Professor Cullen Buie and former MIT postdoc and research scientist Paolo Garcia, offers a solution that could lead to the mass production of genetically engineered cells. Here, Buie answers some questions about how Kytopen has grown since its founding.
Read the Q+A >>